Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 6Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Venous Thrombosis 1Thromboembolism 1Postoperative Complications 1Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Fondaparinux × Clear all
NCT00539942 2017-03-27

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

University of Alabama at Birmingham

Phase 3 Terminated
7 enrolled 9 charts

Postoperative Complications, Venous Thrombosis

NCT00423683 2016-06-08

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

Northwell Health

Phase 3 Terminated
64 enrolled 9 charts

Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡